royalties on roughly $25 million in sales of Vimovo at AstraZeneca ( AZN ) and $3.0 million in licensing revenue relating ..... roughly $91 million in worldwide sales of Vimovo at AstraZeneca and $4.0 million in amortized recognition of the PA
Amarin ( AMRN ) sues Omthera Pharmaceuticals, now part of AstraZeneca ( AZN ), claiming its cholesterol-lowering drug, Epanova , infringes on one of Vascepa's patents. Epanova's target user
March 3 (Reuters) - AstraZeneca PLC : * US FDA approves bydureon pen for once-weekly treatment of adults with type
Feb 25 (Reuters) - AstraZeneca PLC : * FDA approves orphan drug Myalept * Myalept, a recombinant ..... for Myalept from Bristol-Myers Squibb company to Astrazeneca * Source text for Eikon: * For more news, please click
Dulaglutide could generate peak annual revenue of $2B vs Victoza's 2013 sales of $2.1B. Other rival drugs include AstraZeneca 's ( AZN ) Byetta and Bydureon. ( PR ) Post your comment!
adjustment to prices by market-makers would take 14.03 points off the index. COMPANY (RIC) DIVIDEND INDEX IMPACT AstraZeneca 190.0 cents 5.49 Barclays
Terms of the deal weren't disclosed. Immunotherapy is one of the hottest areas of cancer research, with Merck, AstraZeneca and Bristol-Myers among those working in the field. ( PR ) Post your comment!
The FDA says it will review clinical trial data for one of AstraZeneca 's ( AZN ) key diabetes drugs, following concerns expressed in a medical journal last year over increased risk of heart failure
Feb 11 (Reuters) - The U.S. Food and Drug Administration said it will review possible heart risks associated with AstraZeneca Plc 's widely-used diabetes drug saxagliptin, marketed as Onglyza and...
(Reuters) - Biotech company Targacept Inc said British drugmaker AstraZeneca would return rights to several pre-clinical compounds, sending the U.S. company's shares down 10 percent in extended...